AGENDA

2024
Margie & Robert E. Petersen
NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM

DAY 1 – Monday, October 28, 5:00-8:00 p.m.

- **5:00–6:00 p.m. – Registration, Fenway Foyer, Hotel Commonwealth**
- **6:00–8:00 p.m. – Welcome Reception & Poster Session**

DAY 2 – Tuesday, October 29, 8:00 a.m.-5:30 p.m.

- **8:00–9:00 a.m. – Breakfast & Registration**

- **9:00–9:05 a.m. – Welcome**

- **9:05-9:35 a.m. – Keynote and Distinguished Service Award Presentation – Viewing Intestinal NETs Through the Lens of Normal Human Enteroendocrine Cell Differentiation**
  Ramesh Shivdasani, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, with introduction by Chrissie Thirlwell, MBBS, PhD

- **9:35–9:45 a.m. – Patient Voice**
  Elaine Nord

SESSION 1: NEN SCREENS & OMICS, 9:45 a.m.-1:45 p.m.

Session Chairs: Chrissie Thirlwell, MBBS, PhD, University of Bristol Medical School and Sharon Gorski, PhD, BC Cancer

- **9:45–10:00 a.m. – Comprehensive Genomic Profiling of an International Patient Cohort Reveals Diagnostic and Prognostic Signatures for Pancreatic Neuroendocrine Neoplasms**
  Aatur Singhi, MD, PhD, University of Pittsburgh

- **10:00–10:15 a.m. – Assessment of the Current and Emerging Criteria for the Histopathological Classification of Lung Neuroendocrine Tumours in the Lungnenomics Project**
  Matthieu Foll, PhD, International Agency for Research on Cancer

- **10:15–10:30 a.m. – Defining the Transcriptomic Profile of Enterochromaffin Cells in SI-NET Patients**
  Netta Mäkinen, PhD, Dana-Farber Cancer Institute

- **10:30–10:45 a.m. – Discussion**

- **10:45–11:15 a.m. – Coffee Break**

- **11:15-11:30 a.m. – Targeting the Surfaceome of Drug Tolerant Persister Cell Populations in Extrapulmonary High-grade Neuroendocrine Carcinomas**
  C. Allison Stewart, PhD, University of Texas MD Anderson Cancer Center

- **11:30-11:45 a.m. – Simplifying NEN Tissue and Liquid Diagnostics Using Novel and Existing General Neuroendocrine Cell Markers**
  Neil Renwick, MD, PhD, Queen's University

- **11:45 a.m.-12:00 p.m. –** **A Systematic NEN Spheroid Drug Screen Reveals a Novel Drug Resistance Mechanism in Small Bowel NETs**
  Po Hien Ear, PhD, University of Iowa

12:00–12:15 p.m. – **Discussion**

12:15–1:45 p.m. – **Lunch & Group Photo**

SESSION 2: NEN TUMOR MICROENVIRONMENT, 1:45–3:45 p.m.

Session Chairs: James Bibb, PhD, University of Arizona Medical School - Phoenix and Iacovos Michael, PhD, Sunnybrook Research Institute

- **1:45–2:00 p.m. –** **Estrogen Receptor Alpha Inhibition Increases 177Lu-DOTATATE Efficacy in a Pre-clinical Neuroendocrine Tumor Model**
  Xavier Keutgen, MD, University of Chicago Medicine

- **2:00–2:15 p.m. –** **Spatial and temporal intratumor heterogeneity of Pancreatic neuroendocrine tumors**
  Jérôme Cros, MD, PhD, INSERM, Université Paris Cité

- **2:15–2:30 p.m. –** **TILs from Pannet Liver Metastasis: In Search of Novel Adoptive Transfer Strategies for the Treatment of Nets**
  Mauro Cives, MD, University of Bari "Aldo Moro"

- **2:30–2:45 p.m. –** **Immunosuppressive Myeloid Signaling in Pancreatic Neuroendocrine Tumors Revealed by Single-nucleus RNA-seq**
  Jeanna Qiu, AB, Harvard Medical School

- **2:45–3:00 p.m. –** **Spatial Profiling of the Pancreatic Neuroendocrine Tumor Microenvironment**
  Christopher Heaphy, PhD, Boston University School of Medicine

- **3:00–3:15 p.m. –** **Discussion**

- **3:15–3:45 p.m. –** **Coffee Break**

SESSION 3: EARLY CAREER LIGHTNING TALKS, 3:45–5:00 p.m.

Session Chairs: Talya Dayton, PhD, EMBL Barcelona, and Dawn Quelle, PhD, University of Iowa

3:45–4:15 p.m. – Lightning Talks:

1. **Preliminary Analysis of the Whole Exome Sequencing Data of 16 cases with Neuroendocrine Cell Hyperplasia for Classification as Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)**
   Hui Yu, MD, PhD, University of Colorado Anschutz Medical Campus

2. **Does Sexual Dimorphism Play a Role in SI-NET and Mesenteric Disease Development?**
   Maria Martins, MSc, University College London

3. **Epigenetic Regulation of Tumor Metastasis in SI-NETs**
   Elham Barazeghi, PhD, Uppsala University

4. **Reconstructing the Evolutionary History of Neuroendocrine Tumor Subtypes**
   Nicolas Alcala, PhD, International Agency for Research on Cancer

5. **Preliminary Results of the COPPER PET in NET Trial: A Randomized, Crossover, Readers Blind, Phase 0/I Study Comparing 61Cu-NODAGA-LM3 and 68Ga-DOTATOC for the Detection of Neuroendocrine Tumors**
   Guillaume Nicolas, MD, University Hospital Basel

6. **Identifying Regulators of GEP-NET Metastasis with in vivo CRISPR Screen**
   William You, HBSc, Sunnybrook Research Institute

- **4:15–4:30 p.m. – Discussion**
- **4:30–4:35 p.m. – Pheo Para Alliance Travel Award Presentation**
- **4:35–5:30 p.m. – Extended Poster Viewing & Happy Hour**
- **5:30 p.m. – End of Day**

DAY 3 – Wednesday October 30, 8:00 a.m.–1:45 p.m.

- **8:00–9:00 a.m. – Breakfast**
- **9:00–9:05 a.m. – Welcome**
- **9:05-9:15 a.m. – Patient Voice, "Get Busy Living"**
  Carrie Camino, NETRF Board of Directors

SESSION 4: NEN THERAPIES & RESISTANCE MECHANISMS, 9:15–10:30 a.m.

Session Chairs: Mauro Cives, MD, University of Bari "Aldo Moro" and Amanda Wasylishen, PhD, University of Cincinnati

- **9:15–9:30 a.m. – Chimeric Antigen Receptor (CAR) Trogocytosis from CDH17CAR T Cells to Tumor Cells is Crucial for Assessing CAR T Antitumor Activity**
  Xianxin Hua, MD, PhD, University of Pennsylvania

- **9:30–9:45 a.m. – A Novel Hormone Based Anti-SSTR bispecific T-cell Engager for the Treatment of Neuroendocrine Tumors**
  Eleonora Pellé, MD, Moffitt Cancer Center

- **9:45–10:00 a.m. – Deciphering the Responses and Resistance to Anti-angiogenic Therapies in PanNET Liver Metastases**
  Minah Kim, PhD, Columbia University

- **10:00–10:15 a.m. – Elucidating the Role of HMGB3 During the Progression and Response to Radiation Therapy of Pancreatic Neuroendocrine Tumors**
  Iacovos Michael, PhD, Sunnybrook Research Institute

- **10:15 a.m.–10:30 a.m. – Expression of Bromodomain and Extra-terminal (BET) Proteins in Pancreatic Neuroendocrine Tumors and Mechanistic Implications of BET BD1- and BD2-selective Inhibition**
  Omair Shariq, MD, PhD, University of Oxford

- **10:30–10:45 a.m. – What Drives Radiation Response to Peptide Receptor Radionuclide Therapy? Insights from Whole Genome and Exome Sequencing of Pancreatic Neuroendocrine Tumors**
  Emma Boehm, MD, Peter MacCallum Cancer Centre

- **10:45-11:00 a.m. –** **Proteogenomic Characterization of Pancreatic Neuroendocrine Tumors Uncovers Hypoxia and Immune Signature Enrichment in Clinically Aggressive Subtypes**
  Michael Roehrl, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School

- **11:00-11:15 a.m. –** **Discussion**

- **11:15-11:45 a.m. –** **Break & Grab Lunch**

SESSION 5: NEN MODELS & PROGRESSION MECHANISMS, 11:45 a.m.–1:45 p.m.

Session Chairs: Christopher Heaphy, PhD, Boston University School of Medicine and Eleonora Pellé, MD, Moffitt Cancer Center

- **11:45 a.m.–12:00 p.m. –** **DNA Methylation Alterations in Small Intestinal Neuroendocrine Tumours Reveal Candidate Drivers and Independent Epigenetic Evolution**
  Chrissie Thirlwell, MBBS, PhD, University of Bristol Medical School

- **12:00–12:15 p.m. –** **Using Patient-derived Tumor Organoids to Uncover Mechanisms of Pulmonary Net Progression**
  Talya Dayton, PhD, European Molecular Biology Lab (EMBL), Barcelona

- **12:15–12:30 p.m. –** **Cellular and Molecular Diversity of Human Pulmonary Neuroendocrine Cells**
  Christin Kuo, MD, Stanford University

- **12:30–12:45 p.m. –** **The Daxx/Atrx/H3.3 Epigenetic Regulatory Axis in Cell State Regulation and Pancreatic Neuroendocrine Tumor Suppression**
  Amanda Wasylishen, PhD, University of Cincinnati

- **12:45–1:00 p.m. –** **Exploring the Role of a Novel Adrenomedullary Stem Cell Population in Pheochromocytoma/Paraganglioma Tumourigenesis**
  Yasmine Kemkem, PhD, King's College London

- **1:00–1:15 p.m. –** **Development of Innovative in vitro and in vivo Patient-derived Cancer Models for Translational Studies in G1/G2 Gastroenteropancreatic Neuroendocrine Tumors**
  Yi Liu, PhD, University of Texas MD Anderson Cancer Center

- **1:15–1:30 p.m. –** **Discussion**

- **1:30–1:45 p.m. –** **Close of Meeting**